The most important class of medications to manage dyslipidemia due to insulin resistance can be PPARα agonists such as fibrates, because PPARα agonists induce a greater reduction of TG and a greater increase of HDL-C [64]. This evidence concerns the gene PPARA and metabolic syndrome.